Allergic Bronchopulmonary Aspergillosis Therapeutics Market Will Grow at a 5.3% CAGR by 2030: Growth Plus Reports

Newark, New Castle, USA, March 22, 2023 (GLOBE NEWSWIRE) — The Global Allergic Bronchopulmonary Aspergillosis Therapeutics Market is expected to grow at a CAGR of 5.3% from 2022 to 2030, owing to rising prevalence respiratory disorders and presence of a strong product pipeline.  

Market Drivers

The primary factor for the global allergic bronchopulmonary aspergillosis therapeutics market growth is the increased prevalence of respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and pneumonia. According to the National Center for Biotechnology Information, allergic bronchopulmonary aspergillosis (ABPA) affects about 4 million people globally. The presence of a strong product pipeline for allergic bronchopulmonary aspergillosis is another important element driving the expansion of the global market. The total investment in R&D to create new medications to treat aspergillosis has increased. For the development of new pharmaceuticals, the key market players are also implementing strategies like partnering and acquisition, boosting the growth of the global market. Similarly, the ongoing introduction of new treatments and growing public awareness of the need to treat allergic bronchopulmonary aspergillosis promote global market expansion.

The global allergic bronchopulmonary aspergillosis therapeutics market has been analyzed from three perspectives – drug class, route of administration, and region.

Request Free Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/allergic-bronchopulmonary-aspergillosis-therapeutics-market/8072

Allergic Bronchopulmonary Aspergillosis Therapeutics Market Scope

Excerpts from ‘By Drug Class Segmentation’

Based on drug class, the global allergic bronchopulmonary aspergillosis therapeutics market is divided into:

• Azoles
• Antibiotics
• Corticosteroids

The corticosteroids hold the largest market share of the global market in 2021. The major therapy for allergic bronchopulmonary aspergillosis is systemic corticosteroids. Additionally, by helping to relieve symptoms, reduce airflow obstructions, lower serum IgE, and lower peripheral blood eosinophil levels, steroids help to increase the demand for corticosteroids. Additionally, it prevents irreversible lung injury and eliminates pulmonary inflammation and infiltrates, promoting segment growth. The corticosteroids for allergic bronchopulmonary aspergillosis therapeutics market is growing since corticosteroids are the first-line therapy for allergic bronchopulmonary aspergillosis in cystic fibrosis and asthma.

Excerpts from ‘By Route of Administration Segmentation’

Based on the route of administration, the global allergic bronchopulmonary aspergillosis therapeutics market is segmented into:

• Oral
• Parenteral
• Inhalation
• Others

The oral allergic bronchopulmonary aspergillosis therapeutics segment occupied the largest revenue share in 2021. Given that it is the primary form of treatment for ABPA, oral portions account for a significant share. Oral prednisone, itraconazole, and voriconazole are widely recommended as the first line of therapy along with corticosteroid usage because they reduce inflammation, diminish fungal burden, and act as steroid-sparing agents.

Excerpts from ‘By Region Segmentation’

Based on region, the global allergic bronchopulmonary aspergillosis therapeutics market has been segmented into:

• North America
• Europe
• Asia Pacific
• Rest of the World

North America dominated the global allergic bronchopulmonary aspergillosis therapeutics market in 2021. The increased frequency of respiratory disorders such as cystic fibrosis and asthma can be ascribed to a significant share of North America. Additionally, the presence of major market players and the developed healthcare system contribute to the North America allergic bronchopulmonary aspergillosis therapeutics market growth. The well-established biotech and pharma enterprises, as well as increased R&D investment, are fueling the regional market growth. The government organizations in the area are raising awareness about aspergillosis treatment, which is anticipated to spur regional growth.

Request for Customization – https://www.growthplusreports.com/inquiry/customization/allergic-bronchopulmonary-aspergillosis-therapeutics-market/8072

Excerpts from ‘Competitive Landscape’

The prominent players operating in the global allergic bronchopulmonary aspergillosis therapeutics market are:

• Johnson & Johnson
• Pfizer Inc.
• Merck & Co. Inc.
• Astellas Pharma US Inc.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• F2G Ltd.
• Regeneron Pharmaceuticals Inc.
• Biosergen AB
• Zambon SpA
• PULMATRiX Inc.
• Scynexis Inc.
• Pulmocide Ltd.

Table of Content

1. INTRODUCTION
   1. Market Ecosystem
   2. Timeline Under Consideration
      1. Historical Years – 2020
      2. Base Year – 2021
      3. Forecasted Years – 2022 to 2030
   3. Currency Used in the Report
2. RESEARCH METHODOLOGY 
   1. Research Approach
   2. Data Collection Methodology
   3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
   4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
   5. Market Forecasting Model
   6. Limitations and Assumptions
3. PREMIUM INSIGHTS
   1. Current Market Trends (COVID-19 Perspective)
   2. Key Players & Competitive Positioning (2021) 
4. MARKET DYNAMICS
   1. Drivers
   2. Restraints/Challenges
   3. Opportunities
5. GLOBAL ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS THERAPEUTICS MARKET – ANALYSIS & FORECAST, BY DRUG CLASS
   1. Azoles
   2. Antibiotics
   3. Corticosteroids
   4. Others
6. GLOBAL ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS THERAPEUTICS MARKET – ANALYSIS & FORECAST, BY ROUTE OF ADMINISTRATION
   1. Oral
   2. Parenteral
   3. Inhalation

TOC Continued.

Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8072

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• ‘Business Profile’ of Key Players

Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction

Visit our report store at – https://www.growthplusreports.com/report-store

Browse related reports:

Virus-like Particles Market by Type (Vaccines, Therapeutics), Source (Yeast, Plant, Insect Cell), Application (Hepatitis, Gaucher Disease) – Global Outlook and Forecast 2023-2031 by Type (Vaccines, Therapeutics), Source (Yeast, Plant, Insect Cell), Application (Hepatitis, Gaucher Disease) – Global Outlook and Forecast 2023-2031

Scleral Lens Market by Type (Mini Scleral Lens and Large Scleral Lens), Application (Ocular Surface Disease, Irregular Cornea), and End User (Hospitals, Eye Clinics) – Global Outlook & Forecast 2023-2031

Steam Autoclave Market by Product Type (Tabletop Autoclaves, Vertical Steam Autoclaves), End-user (Hospitals and Clinics, Pharmaceutical and Biotechnology Companies) – Global Outlook & Forecast 2023-2031

RNase and DNase Free Pipette Tips Market by Volume (10 µL, 200 µL), End-user (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes) – Global Outlook and Forecast 2023-2031

Periodontal Therapeutics Market by Drug Type (Antibiotics, Antiseptics) and End User (Hospitals, Dental Clinics) – Global Outlook & Forecast 2023-2031

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.